Prof. Alok Srivastava
Head, Haematology Research Unit & Sr. Consultant, Clinical Haematology
Prof. Srivastava has been involved with the management of patients with inherited bleeding disorders for over 30 years. His recent focus has been on novel therapies including gene therapy for hemophilia. Prof. Srivastava is Board Member of the World Federation of Hemophilia, Chairman of the Association for Haemophilia & Allied Disorders – Asia-Pacific, President of the Indian Association for Haemophilia & Allied Disorders as well as President of the Indian Association for Cell and Gene Therapy. He was the chair of the FVIII/IX subcommittee of the SSC of the ISTH from 2006-2010 and currently serves on the ISTH SSC Gene Therapy steering committee. He was the WFH Vice-President (Medical) from 2012-2014 and is currently also a member of the board of the WFH. He has led the writing group for all three editions of the WFH guidelines for the management of hemophilia. His group pioneered the first in human haematopoietic stem cell based lentiviral vector mediated gene therapy for haemophilia A. He has over 450 peer-reviewed scientific publications.
